You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aberration-correcting Topologically Optimized Metasurface (ATOM)
SBC: PHYSICAL SCIENCES INC. Topic: HR001119S003524Metalenses, with their ability to arbitrarily control the amplitude and phase of light across a band of wavelengths, have the potential to disrupt imaging and communication systems which rely on traditional lenses to focus, collimate, and otherwise manipulate optical signals, and are under increasing pressure to operate with reduced size and weight. We propose to design, develop, and demonstrate a ...
STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency -
A Genes-to-Molecules Platform for Expanding Natural Product Diversity
SBC: Lassogen, Inc. Topic: NCCIHProject Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation
SBC: REBISCAN, Inc. Topic: NProject Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A novel device for cervical insufficiency in pregnant women
SBC: Cx Therapeutics, Inc Topic: NICHDAbstract In normal pregnancy, the cervix remains closed until term and then dilates under the influence of uterine contractions. In cases of cervical insufficiency (CI), the cervix dilates in the second trimester in the absence of uterine contractions, which leads to a preterm birth. Infants born prematurely are at risk of lifelong morbidities including chronic lung disease, feeding difficulties, ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids
SBC: SEACOAST SCIENCE, INC. Topic: NIDAAbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A novel role for Reelin therapeutics in inflammatory bowel disease
SBC: REELIN THERAPEUTICS, INC. Topic: 300Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Novel Therapeutic Agent for the Treatment of Gram-positive Infections
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary The work described in the application is necessary for furthering the development of a new therapeutic for treating Gram-positive infections. Preliminary in vitro and in vivo activity studies of novel analogs of mutacin 1140 suggest that they hold great promise as an antimicrobial product for clinical use. Mutacin 1140 is produced by the bacterium Streptococcus mutans JH1140 and th ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A platform for engineering peptide ligase for building next generation peptide therapeutics.
SBC: SCRIBE BIOSCIENCES, INC. Topic: 400PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging
SBC: PETcoil, Inc. Topic: 101Project Summary Medical imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have been widely used in studying the underlying mechanisms of mental illnesses and neurological disorders such as brain tumors, Alzheimer’s disease, epilepsy, and depression, etc. However, PET and MRI scans are almost always ordered as separate studies on separate machine ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Application of TNFRSF25 agonists for prophylaxis and treatment of graft versus host disease
SBC: PELICAN THERAPEUTICS, INC. Topic: NIAIDPROJECT SUMMARY Graft-vs-Host-Disease (GVHD) is a frequent and life-threatening complication of hematopoietic stem cell transplantation (HSCT), a procedure that often represents the best treatment option for patients suffering from hematological malignancies. Even when HLA-matched family or unrelated donors are available, an unsatisfactorily high frequency (30-40%) of transplant recipients still d ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health